| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Pyridoxal-d3 hydrochloride shares the same molecular target as its non-deuterated form, pyridoxal. Pyridoxal is a form of vitamin B6 that is converted in the body to pyridoxal 5-phosphate (PLP), the active coenzyme form. PLP serves as a cofactor for over 140 enzymes involved in amino acid metabolism, neurotransmitter synthesis, glycogenolysis, and hemoglobin synthesis. PLP-dependent enzymes include transaminases, decarboxylases, racemases, and synthases. The labeled compound is used as a tracer to study vitamin B6 metabolism and PLP-dependent enzymatic reactions.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
The deuterated compound itself does not possess intrinsic pharmacological activity in vitro; its biological activity is identical to that of pyridoxal. Pyridoxal is a precursor to PLP, which is an essential coenzyme for numerous enzymatic reactions. In vitro, PLP is required for the activity of many enzymes, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Pyridoxal can also act as an antioxidant and has been shown to scavenge reactive oxygen species. The labeled compound is used as an internal standard for quantifying vitamin B6 vitamers in biological samples. |
| ln Vivo |
Pyridoxal-d3 hydrochloride is not used as a therapeutic agent; its non-deuterated form, pyridoxal, is a natural form of vitamin B6 that is converted in the body to the active coenzyme PLP. Vitamin B6 is essential for normal brain development, immune function, and the synthesis of neurotransmitters such as serotonin, dopamine, and GABA. Vitamin B6 deficiency can lead to neurological disorders, anemia, and cardiovascular disease. The labeled compound is used in pharmacokinetic and metabolic studies to accurately measure vitamin B6 levels in biological samples.
|
| Enzyme Assay |
In vitro assays for pyridoxal-d3 hydrochloride focus on its use as an analytical standard rather than a receptor-binding agent. A standard protocol for vitamin B6 analysis involves preparing a solution of the compound in an appropriate solvent (e.g., water or methanol) and using it as an internal standard for LC-MS/MS analysis. The compound is added to biological samples (e.g., plasma, urine, or tissue homogenates) before extraction and derivatization procedures. Quantification is performed by monitoring specific mass transitions for the labeled and unlabeled compounds. Quality control includes purity analysis.
|
| Cell Assay |
In vitro cell culture experiments are not performed with pyridoxal-d3 hydrochloride. When studying the effects of vitamin B6 in cellular systems, the non-labeled compound is used. Cells are treated with pyridoxal or PLP, and enzyme activities, neurotransmitter levels, or gene expression are measured. The labeled compound is used as an internal standard for LC-MS/MS analysis of vitamin B6 concentrations in cell culture media or lysates.
|
| Animal Protocol |
In vivo animal studies are not conducted with pyridoxal-d3 hydrochloride. When used in pharmacokinetic studies, the labeled compound serves as an internal standard for the quantification of vitamin B6 vitamers in animal plasma or tissue samples. In typical protocols, animals are administered vitamin B6, and blood and tissue samples are collected at various time points. The labeled internal standard is added to the samples before analysis by LC-MS/MS to ensure accurate and precise quantification.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of pyridoxal-d3 hydrochloride itself are not characterized, as it is not a drug substance. Pyridoxal is absorbed in the small intestine and converted to PLP in the liver. PLP is the major circulating form of vitamin B6 and is excreted in urine as pyridoxal and 4-pyridoxic acid. The half-life of PLP is approximately 15-20 days. The labeled compound is used as an internal standard to accurately quantify vitamin B6 vitamers in pharmacokinetic studies.
|
| Toxicity/Toxicokinetics |
Pyridoxal-d3 hydrochloride is not a therapeutic agent and has not been evaluated for toxicity in humans. Its non-deuterated form, pyridoxal, is a natural form of vitamin B6 that is generally recognized as safe (GRAS) at recommended doses. High doses of vitamin B6 can cause neuropathy. The labeled compound is for research use only and should be handled with standard laboratory precautions.
|
| References | |
| Additional Infomation |
Pyridoxal-d3 hydrochloride is a stable isotope-labeled internal standard used in studies of vitamin B6 metabolism, enzyme mechanisms, and neurological and metabolic disorders. It is also known as pyridoxaldehyde-d3 hydrochloride. The compound is used in analytical method development, quality control, and biomonitoring studies. The incorporation of deuterium allows for accurate quantification of vitamin B6 vitamers in biological samples using mass spectrometry.
|
| Molecular Formula |
C8H10CLNO3
|
|---|---|
| Molecular Weight |
203.622901439667
|
| Exact Mass |
206.053
|
| CAS # |
1173023-49-8
|
| Related CAS # |
Pyridoxal;66-72-8;Pyridoxal-d3;1173148-04-3
|
| PubChem CID |
53442250
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
13
|
| Complexity |
162
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=NC=C(C(=C1O)C=O)CO.Cl
|
| InChi Key |
FCHXJFJNDJXENQ-NIIDSAIPSA-N
|
| InChi Code |
InChI=1S/C8H9NO3.ClH/c1-5-8(12)7(4-11)6(3-10)2-9-5;/h2,4,10,12H,3H2,1H3;1H/i1D3;
|
| Chemical Name |
3-hydroxy-5-(hydroxymethyl)-2-(trideuteriomethyl)pyridine-4-carbaldehyde;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9111 mL | 24.5555 mL | 49.1111 mL | |
| 5 mM | 0.9822 mL | 4.9111 mL | 9.8222 mL | |
| 10 mM | 0.4911 mL | 2.4556 mL | 4.9111 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
